Roger Newton is Executive Chairman and Chief Scientific Officer of Esperion Therapeutics
Tim Mayleben is President and Chief Executive Officer of Esperion Therapeutics
Esperion Therapeutics is a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density, lipoprotein cholesterol (LDL-C) lowering therapies for treatment of hypercholesterolemia and other cardiometabolic risk markers.
In their conversation with Paul Krutko, president and CEO of Ann Arbor SPARK, Roger (who is also a SPARK board member) and Tim discuss Esperion’s focus, being acquired by and then re-emerging from Pfizer, and how economic development organizations like MEDC have assisted Esperion with its growth.
Subscribe to our newsletters
Don’t miss an event, announcement, or job opportunity. Get news delivered to your inbox and stay informed about what is going on in tech, business, and talent in the greater Ann Arbor region.
Subscribe to our newsletters
Don’t miss an event, announcement, or job opportunity. Get news delivered to your inbox and stay informed about what is going on in tech, business, and talent in the greater Ann Arbor region.